MiMedx To Acquire Sanara MedTech In $350 Million Deal; Stock Up
MiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.
How this was made
The 30-second read
Why it matters
The acquisition combines Sanara’s surgical technologies with MiMedx’s portfolio, aiming to expand operating room presence and deliver revenue growth plus cost synergies.
Market read
A disclosed $35/share, ~$350 million acquisition with management-stated 2027 targets is a direct catalyst for MDXG and deal-spread positioning.
What to watch
Closing conditions, financing structure, and any FDA/commercial adoption timelines for OsStic BioAdhesive are not detailed here, which can materially affect valuation.
Background
MiMedx (MDXG) is a regenerative medicines biopharma company; Sanara (SMTI) focuses on regenerative surgical products and is preparing a 2027 commercial launch of OsStic BioAdhesive.
Ticker impact
MiMedx agreed to acquire Sanara MedTech for about $350 million, projecting 2027 revenue above $400 million and EBITDA margins above 20%.
Likely supportive for MDXG while deal completion risk remains, with volatility around regulatory/closing milestones.
The article discloses a specific $35/share offer, deal value, and management-stated 2027 financial targets, which are actionable for deal-spread and positioning.
Market effects
Signals continued consolidation in regenerative surgical products, potentially improving sentiment for adjacent surgical device and regenerative medicine names.
Primarily US-focused biotech M&A sentiment.
Limited direct global read-through beyond US regenerative surgery consolidation.
Counterpoint
Projected 2027 revenue and EBITDA margins may be optimistic versus execution and integration risk, so the deal spread could widen if diligence or regulatory hurdles emerge.
Key entities
- acquirerMiMed Group Inc.
Agreed to acquire Sanara MedTech in a transaction valued at about $350 million.
- targetSanara MedTech Inc.
Flagship regenerative surgical products and preparing a 2027 commercial launch of OsStic BioAdhesive.
- productOsStic BioAdhesive Advanced Bone Fixation
A device designated as Breakthrough by the U.S. FDA, targeted for 2027 commercial launch.
